<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00445965</url>
  </required_header>
  <id_info>
    <org_study_id>05-122</org_study_id>
    <secondary_id>MSKCC-05122</secondary_id>
    <nct_id>NCT00445965</nct_id>
  </id_info>
  <brief_title>Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer</brief_title>
  <official_title>Phase II Study of Intrathecal I-3F8 in Patients With GD2-Expressing Central Nervous System and Leptomeningeal Neoplasms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Radiolabeled monoclonal antibodies, such as iodine I 131 monoclonal antibody 3F8,&#xD;
      can find tumor cells and carry tumor-killing substances to them without harming normal cells.&#xD;
      This may be an effective treatment for central nervous system cancer or leptomeningeal&#xD;
      metastases.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying the side effects and how well iodine I 131&#xD;
      monoclonal antibody 3F8 works in treating patients with central nervous system cancer or&#xD;
      leptomeningeal cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine if intrathecal iodine I 131 monoclonal antibody 3F8 activity in patients with&#xD;
           GD2-expressing central nervous system or leptomeningeal neoplasms is sufficiently&#xD;
           promising (i.e., 6-month overall survival rate â‰¥ 25%) to warrant further study.&#xD;
&#xD;
        -  Determine the response rate in patients treated with this drug.&#xD;
&#xD;
        -  Determine the cumulative toxicities of this drug in these patients.&#xD;
&#xD;
        -  Describe the effects of human-antimouse antibody on cerebrospinal fluid and serum&#xD;
           pharmacokinetics in patients treated with this drug.&#xD;
&#xD;
      OUTLINE: This is an open-label study.&#xD;
&#xD;
      Patients receive intrathecal iodine I 131 monoclonal antibody 3F8 for dosimetry. Beginning&#xD;
      approximately 1 week later, patients receive intrathecal iodine I 131 monoclonal antibody 3F8&#xD;
      on day 1. Treatment intrathecal iodine I 131 monoclonal antibody 3F8 repeats weekly for up to&#xD;
      4 courses in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Blood and cerebrospinal fluid samples are collected prior to and after administration of each&#xD;
      course of study drug. Samples are analyzed to assess the intrathecal and blood&#xD;
      pharmacokinetics of iodine I 131 monoclonal antibody 3F8 and serum human antimouse&#xD;
      antibodies. Samples are also analyzed in tumor genetic studies.&#xD;
&#xD;
      After completion of study treatment, patients are followed periodically for 3 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 2006</start_date>
  <completion_date type="Anticipated">January 2023</completion_date>
  <primary_completion_date type="Anticipated">January 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Six-month overall survival</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>response rate</measure>
    <time_frame>6 months</time_frame>
    <description>A &quot;response&quot; is defined as a patient being alive six months after their first treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>cumulative toxicities</measure>
    <time_frame>1 year</time_frame>
    <description>Toxicities will be assessed via the NCI toxicity criteria (CTC 3.0).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">78</enrollment>
  <condition>Brain and Central Nervous System Tumors</condition>
  <condition>Intraocular Melanoma</condition>
  <condition>Lung Cancer</condition>
  <condition>Melanoma (Skin)</condition>
  <condition>Metastatic Cancer</condition>
  <condition>Neuroblastoma</condition>
  <condition>Ovarian Cancer</condition>
  <condition>Retinoblastoma</condition>
  <condition>Sarcoma</condition>
  <condition>Small Intestine Cancer</condition>
  <arm_group>
    <arm_group_label>131I-3F8</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This is a phase II single-arm open-label study that will define responses to therapy with weekly intrathecal 131I-3F8 in patients with central nervous system/leptomeningeal GD2-expressing disease.</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>DNA analysis</intervention_name>
    <arm_group_label>131I-3F8</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>immunologic technique</intervention_name>
    <arm_group_label>131I-3F8</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
    <arm_group_label>131I-3F8</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>iodine I 131 monoclonal antibody 3F8</intervention_name>
    <arm_group_label>131I-3F8</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>131I-3F8</intervention_name>
    <description>Patients will receive 10mCi intrathecal 131I-3F8 per week. Patients will be pre-medicated with dexamethasone to prevent possible meningeal inflammatory reaction, Liothyronine and SSKI to prevent thyroid accumulation, and acetaminophen and diphenhydramine in anticipation of possible allergic reaction and fever.</description>
    <arm_group_label>131I-3F8</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must have a histologically confirmed diagnosis of a malignancy known to&#xD;
             expressGD2. Such tumors include medulloblastoma/primitive neuroectodermal tumor of the&#xD;
             CNS, high grade astrocytomas, malignant glioma, neuroblastoma, retinoblastoma,&#xD;
             ependymoma, rhabdoid tumors, sarcomas, melanoma or small cell lung carcinoma. For&#xD;
             patients with other tumor types, GD2 expression must be confirmed by&#xD;
             immunohistochemical staining and assessed by the Department of Pathology using prior&#xD;
             frozen tissue, bone marrow or CSF cytology (send to Research Lab).&#xD;
&#xD;
          -  Patients must have CNS/ leptomeningeal disease including high risk medulloblastoma, or&#xD;
             a CNS/leptomeningeal malignancy which is refractory to conventional therapies, or for&#xD;
             which no conventional therapy exists, OR a recurrent brain tumors with a predilection&#xD;
             for leptomeningeal dissemination (medulloblastoma, PNET, rhabdoid tumor).&#xD;
&#xD;
          -  Patients must have an absolute neutrophil count (ANC) &gt; 1000/ul and a platelet count &gt;&#xD;
             50,000/ul.&#xD;
&#xD;
          -  Patients may have active malignancy outside the central nervous system.&#xD;
&#xD;
          -  Patients who have a programmable shunt will not be excluded.&#xD;
&#xD;
          -  Both pediatric and adult patients of any age are eligible.&#xD;
&#xD;
          -  Patients or a legal guardian will sign an informed consent form approved by the IRB&#xD;
             and obtained by the Principal or a Co- Investigator before patient entry. Minors will&#xD;
             provide assent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with obstructive or symptomatic communicating hydrocephalus.&#xD;
&#xD;
          -  Patients with an uncontrolled life-threatening infection.&#xD;
&#xD;
          -  Patients who are pregnant: Pregnant women are excluded for fear of danger to the&#xD;
             fetus. Therefore negative pregnancy test is required for all women of child-bearing&#xD;
             age, and appropriate contraception is required during the study period.&#xD;
&#xD;
          -  Patients who have received cranial or spinal irradiation less than 3 weeks prior to&#xD;
             the start of this protocol.&#xD;
&#xD;
          -  Patients who have received systemic chemotherapy (corticosteroids not included) less&#xD;
             than 3 weeks prior to the start of this protocol.&#xD;
&#xD;
          -  Severe major organ toxicity. Specifically, renal, cardiac, hepatic, pulmonary, and&#xD;
             gastrointestinal system toxicity should all be less than or equal to grade 2. Patients&#xD;
             with stable neurological deficits (because of their brain tumor) are not excluded.&#xD;
             Patients with &lt;= 3 hearing loss are not excluded.&#xD;
&#xD;
          -  Patients must have no rapidly progressing or deteriorating neurologic examination.&#xD;
&#xD;
          -  Patients who have already received &gt;45 Gy to the craniospinal radiation or &gt;72 Gy&#xD;
             focal brain radiation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kim Kramer, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>March 7, 2007</study_first_submitted>
  <study_first_submitted_qc>March 7, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 9, 2007</study_first_posted>
  <last_update_submitted>October 28, 2021</last_update_submitted>
  <last_update_submitted_qc>October 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent childhood medulloblastoma</keyword>
  <keyword>untreated childhood medulloblastoma</keyword>
  <keyword>adult supratentorial primitive neuroectodermal tumor (PNET)</keyword>
  <keyword>recurrent childhood supratentorial primitive neuroectodermal tumor</keyword>
  <keyword>untreated childhood supratentorial primitive neuroectodermal tumor</keyword>
  <keyword>adult anaplastic astrocytoma</keyword>
  <keyword>adult diffuse astrocytoma</keyword>
  <keyword>adult pilocytic astrocytoma</keyword>
  <keyword>adult subependymal giant cell astrocytoma</keyword>
  <keyword>recurrent childhood subependymal giant cell astrocytoma</keyword>
  <keyword>untreated childhood subependymal giant cell astrocytoma</keyword>
  <keyword>recurrent childhood cerebellar astrocytoma</keyword>
  <keyword>recurrent childhood cerebral astrocytoma</keyword>
  <keyword>untreated childhood cerebellar astrocytoma</keyword>
  <keyword>adult brain stem glioma</keyword>
  <keyword>adult mixed glioma</keyword>
  <keyword>childhood mixed glioma</keyword>
  <keyword>recurrent childhood brain stem glioma</keyword>
  <keyword>recurrent childhood visual pathway and hypothalamic glioma</keyword>
  <keyword>recurrent childhood visual pathway glioma</keyword>
  <keyword>untreated childhood brain stem glioma</keyword>
  <keyword>untreated childhood visual pathway and hypothalamic glioma</keyword>
  <keyword>untreated childhood visual pathway glioma</keyword>
  <keyword>regional neuroblastoma</keyword>
  <keyword>disseminated neuroblastoma</keyword>
  <keyword>recurrent neuroblastoma</keyword>
  <keyword>extraocular retinoblastoma</keyword>
  <keyword>recurrent retinoblastoma</keyword>
  <keyword>adult anaplastic ependymoma</keyword>
  <keyword>adult ependymoblastoma</keyword>
  <keyword>adult ependymoma</keyword>
  <keyword>adult myxopapillary ependymoma</keyword>
  <keyword>adult subependymoma</keyword>
  <keyword>childhood infratentorial ependymoma</keyword>
  <keyword>childhood supratentorial ependymoma</keyword>
  <keyword>recurrent childhood ependymoma</keyword>
  <keyword>childhood atypical teratoid/rhabdoid tumor</keyword>
  <keyword>recurrent melanoma</keyword>
  <keyword>stage IV melanoma</keyword>
  <keyword>adult medulloblastoma</keyword>
  <keyword>chondrosarcoma</keyword>
  <keyword>metastatic osteosarcoma</keyword>
  <keyword>recurrent osteosarcoma</keyword>
  <keyword>metastatic childhood soft tissue sarcoma</keyword>
  <keyword>ovarian sarcoma</keyword>
  <keyword>recurrent childhood soft tissue sarcoma</keyword>
  <keyword>stage III adult soft tissue sarcoma</keyword>
  <keyword>stage IV adult soft tissue sarcoma</keyword>
  <keyword>stage III uterine sarcoma</keyword>
  <keyword>stage IV uterine sarcoma</keyword>
  <keyword>previously treated childhood rhabdomyosarcoma</keyword>
  <keyword>recurrent childhood rhabdomyosarcoma</keyword>
  <keyword>adult anaplastic oligodendroglioma</keyword>
  <keyword>adult desmoplastic small round cell tumor</keyword>
  <keyword>adult oligodendroglioma</keyword>
  <keyword>adult giant cell glioblastoma</keyword>
  <keyword>adult gliosarcoma</keyword>
  <keyword>tumors metastatic to brain</keyword>
  <keyword>adult rhabdomyosarcoma</keyword>
  <keyword>childhood oligodendroglioma</keyword>
  <keyword>childhood desmoplastic small round cell tumor</keyword>
  <keyword>extensive stage small cell lung cancer</keyword>
  <keyword>intraocular retinoblastoma</keyword>
  <keyword>recurrent adult brain tumor</keyword>
  <keyword>recurrent adult soft tissue sarcoma</keyword>
  <keyword>recurrent uterine sarcoma</keyword>
  <keyword>small intestine leiomyosarcoma</keyword>
  <keyword>recurrent small intestine cancer</keyword>
  <keyword>recurrent small cell lung cancer</keyword>
  <keyword>extraocular extension melanoma</keyword>
  <keyword>recurrent intraocular melanoma</keyword>
  <keyword>metastatic intraocular melanoma</keyword>
  <keyword>iris melanoma</keyword>
  <keyword>ciliary body and choroid melanoma, medium/large size</keyword>
  <keyword>newly diagnosed childhood ependymoma</keyword>
  <keyword>adult glioblastoma</keyword>
  <keyword>metastatic Ewing sarcoma/peripheral primitive neuroectodermal tumor</keyword>
  <keyword>recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor</keyword>
  <keyword>recurrent childhood pineoblastoma</keyword>
  <keyword>untreated childhood pineoblastoma</keyword>
  <keyword>adult pineal gland astrocytoma</keyword>
  <keyword>stage IIIA melanoma</keyword>
  <keyword>stage IIIB melanoma</keyword>
  <keyword>stage IIIC melanoma</keyword>
  <keyword>recurrent childhood anaplastic astrocytoma</keyword>
  <keyword>untreated childhood anaplastic astrocytoma</keyword>
  <keyword>recurrent childhood anaplastic oligoastrocytoma</keyword>
  <keyword>recurrent childhood anaplastic oligodendroglioma</keyword>
  <keyword>untreated childhood anaplastic oligoastrocytoma</keyword>
  <keyword>untreated childhood anaplastic oligodendroglioma</keyword>
  <keyword>recurrent childhood giant cell glioblastoma</keyword>
  <keyword>recurrent childhood glioblastoma</keyword>
  <keyword>untreated childhood giant cell glioblastoma</keyword>
  <keyword>untreated childhood glioblastoma</keyword>
  <keyword>recurrent childhood gliosarcoma</keyword>
  <keyword>untreated childhood gliosarcoma</keyword>
  <keyword>recurrent childhood gliomatosis cerebri</keyword>
  <keyword>untreated childhood gliomatosis cerebri</keyword>
  <keyword>childhood high-grade cerebellar astrocytoma</keyword>
  <keyword>childhood high-grade cerebral astrocytoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Neuroblastoma</mesh_term>
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
    <mesh_term>Retinoblastoma</mesh_term>
    <mesh_term>Intestinal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

